Compare Cronos Group Inc (CRON) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs W W Grainger Inc — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.02B), while W W Grainger Inc trades at $1,374.19 (market cap $64.73B). The key difference: W W Grainger Inc is far larger — about 63.5× Cronos Group Inc's market cap, and W W Grainger Inc pays a 0.68% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | GWW | |
|---|---|---|
Market Cap | $1.02B | $64.73B |
Sector | Health | Technology |
52-Week High | $3.27 | $1.39K |
52-Week Low | $1.95 | $918.18 |
Enterprise Value | $203.29M | $66.82B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
GWW trades at $1,391.68, up 1.16% today, with a bullish technical outlook supported by moving averages and strong momentum. The company reported Q1 2026 EPS of $11.65, beating estimates, and raised its full-year guidance. Revenue growth remains steady, with 2026 revenue projected at $18.4B, while profitability metrics like ROE of 48.1% and net margin near 10% highlight operational strength. Positive analyst sentiment and recent dividend declarations reinforce investor confidence amid a favorable market backdrop.
The outlook for GWW is positive, driven by earnings beats and raised guidance, though valuation multiples like a P/E of 36.87 suggest premium pricing. Risks include economic sensitivity and competitive pressures, but institutional buy ratings and technical support near $1,380 provide a cushion for upward momentum if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
